Sökresultat
Imfinzi plus kemoterapi minskade risken för död med 20% i 1a linjen vid gallvägscancer
…apy reduced risk of death by 20% in 1st-line advanced biliary tract cancer TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting. Combination did not increase discontinuations due to adverse events vs. chemotherapy alone. Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, demonstrated a statistical…
Amgen på ASH 2020 – starka kliniska data och innovativ pipeline
…Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison Abstract #1655, Poster Presentation, Saturday, Dec. 5 from 7:00 a.m. – 3:30 p.m. PT Forskarinitierade abstracts, Kyprolis Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial Abstract #141, Oral Presentation, Saturday, Dec. 5 at 9:30 a.m. PT Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) w…
Hematologernas världskongress i Madrid
…gical cases, Thrombotic thrombocytopenic purpura (TTP): Is plasmapheresis history? Aging and hematology: The clone wars, The impact of aging in mutant clones and development of disease. En del av sessionerna var debatt mellan två experter, och andra ”meet the expert” där oftast ett specifikt scenario eller sjukdom diskuterades medan de flesta var sessions där den senaste forskningen presenterades. Den session som drog till sig flest delegater var…
Lynparza for ”priority review” i USA för BRCA-muterad, HER-2 negativ, tidig bröstcancer med hög risk
…iption Drug User Fee Act date, the FDA action date for their regulatory decision, is during the first quarter of 2022. Breast cancer is now the most diagnosed cancer worldwide with an estimated 2.3 million patients diagnosed in 2020.2 Nearly 91% of all breast cancer patients are diagnosed at an early stage of disease and BRCA mutations are found in approximately 5% of patients.3,4,5 The sNDA was based on results from the OlympiA Phase III trial pr…
Libtayo som monoterapi ökar totalöverlevnaden i första linjens behandling av avancerad NSCLC
…um-based, doublet chemotherapy regimen for 4 to 6 cycles (with or without histology relevant maintenance pemetrexed chemotherapy). The co-primary endpoints are OS and PFS, and secondary endpoints include overall response rate, duration of response and quality of life. The trial was designed to reflect current and emerging treatment paradigms. Inclusion criteria allowed patients with NSCLC who had: controlled hepatitis B, hepatitis C or HIV; pre-tr…